DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Osteoporosis Treatments Affect Bone Matrix Maturation in a Rat Model of Induced Cortical Remodeling

Journal Article · · JBMR Plus
DOI: https://doi.org/10.1002/jbm4.10344 · OSTI ID:1608144
ORCiD logo [1];  [2];  [2];  [3]; ORCiD logo [3]; ORCiD logo [3];  [1]
  1. Department of Cell &, Molecular Medicine Rush University Medical Center Chicago IL USA, Department of Orthopedic Surgery Rush University Medical Center Chicago IL USA
  2. Department of Cell &, Molecular Medicine Rush University Medical Center Chicago IL USA
  3. Clinical Cell Biology, Research Unit of Pathology, Department of Clinical Research University of Southern Denmark, and Department of Pathology, Odense University Hospital Odense Denmark, Department of Molecular Medicine University of Southern Denmark Odense Denmark

ABSTRACT To test how osteoporosis drugs affect bone matrix maturation during cortical bone remodeling, 72 pregnant rats were switched from a 0.4% to a 0.01% calcium diet at parturition for a 23‐day lactation period. At weaning, eight dams were sacrificed to establish baseline values, while the remaining dams were returned to 0.4% calcium and treated with vehicle (saline), sodium fluoride (NaF), zoledronic acid (ZA), or sclerostin antibody (Scl‐Ab) for either 7 or 28 days (eight animals per group per time point). Femora were examined by μCT, dynamic histomorphometry, Fourier transform infrared imaging, and three‐point bending of notched specimens. Cortical porosity decreased in all groups from baseline to day 28. Intracortical mineralizing surface (MS/BS) and mineral apposition rate (MAR), as well as the mineral‐to‐matrix ratio were unaffected by treatment, but intracortical crystallinity was increased in the ZA group at day 10 compared with vehicle. Cortical area increased in all groups over 28 days mainly because of an addition of bone at the endocortical surface. Endocortical MS/BS did not vary among the groups, but endocortical MAR was suppressed in the NaF group at day 2 and elevated in the Scl‐Ab group at day 4 compared with vehicle. Endocortical mineral‐to‐matrix ratio was increased at days 5 and 10 following NaF treatment and endocortical crystallinity was increased at day 5 following ZA treatment compared with vehicle. Fracture toughness did not differ among the groups. Thus, the treatments affected matrix maturation more strongly at the endocortical then intracortical envelope. In this model of induced remodeling, the bone formation phase is synchronized at multiple sites, facilitating study of the effects of drugs or other bone‐targeting agents on matrix maturation independent of their effects on the initiation of remodeling. © 2020 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE; USDOE Office of Science (SC), Basic Energy Sciences (BES)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1608144
Journal Information:
JBMR Plus, Journal Name: JBMR Plus Journal Issue: 4 Vol. 4; ISSN 2473-4039
Publisher:
Oxford University PressCopyright Statement
Country of Publication:
United Kingdom
Language:
English

References (44)

Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee journal December 2012
Bone Matrix Quality After Sclerostin Antibody Treatment: BONE MATRIX COMPOSITION AND SCLEROSTIN ANTIBODY journal June 2014
Adaptations in the Microarchitecture and Load Distribution of Maternal Cortical and Trabecular Bone in Response to Multiple Reproductive Cycles in Rats: EFFECTS OF REPRODUCTION ON BONE MICROARCHITECTURE journal February 2017
Coupling of Bone Resorption and Formation in Real Time: New Knowledge Gained From Human Haversian BMUs: COUPLING IN REAL TIME journal February 2017
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism journal June 2011
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures journal February 2012
Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride journal April 1989
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis journal February 1993
Abnormal bone mineralization after fluoride treatment in osteoporosis: A small-angle x-ray-scattering study journal October 1994
Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the appendicular skeleton in rats journal August 1992
Trabecular stress fractures during fluoride therapy for osteoporosis journal October 1985
The effects of pregnancy and lactation on some mechanical properties of the femora of the rat journal February 1973
Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid journal March 2004
The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats journal September 2011
Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients journal November 2012
Long-Term Zoledronic Acid Treatment Increases Bone Structure and Mechanical Strength of Long Bones of Ovariectomized Adult Rats journal April 2003
Bone Matrix Maturation in a Rat Model of Intra-Cortical Bone Remodeling journal April 2017
Bisphosphonates: effects on osteoblast journal February 2012
Calcium restriction during lactation has minimal effects on post-weaning mineral metabolism and bone recovery journal October 2018
Effects of fluoride in bone repair: an evaluation of RANKL, OPG and TRAP expression journal August 2012
The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime journal January 1991
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women journal November 2000
Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles journal May 2001
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs journal December 2003
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate journal October 2006
The associations between mineral crystallinity and the mechanical properties of human cortical bone journal March 2008
Measurement of the toughness of bone: A tutorial with special reference to small animal studies journal November 2008
Bisphosphonates do not alter the rate of secondary mineralization journal October 2011
A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy journal July 2014
In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy journal January 2008
Imaging the Material Properties of Bone Specimens Using Reflection-Based Infrared Microspectroscopy journal April 2012
Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis journal March 1990
Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance journal July 2017
Bone Fragility of the Peripheral Skeleton During Fluoride Therapy for Osteoporosis journal December 1990
Fluorides and Osteoporosis journal July 1991
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. journal December 1993
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. journal September 1997
Sodium Fluoride Therapy of Postmenopausal Osteoporosis journal June 1993
Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib journal January 2004
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis* journal April 2009
Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib journal April 2000
Long-Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog Vertebra journal March 2003
A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone journal January 2009
Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature journal November 2017